Mecasermin rinfabate
As of the edition of 20 October 2026, Mecasermin rinfabate is a protein: marketed, first approved in 2005 (US); acts on IGF1R; US protection ended in 2017.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2005
- Kind
- Protein
- Brand name
- Iplex
- First approved
- 12 December 2005 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Insmed
- Registered trials
- 2, 0 stopped early
- Disease areas
- Eye; Inherited and neonatal; Lungs and airways
US protection
US protection ended in 2017.
US protection ended in 2017, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by Insmed. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product2 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 2 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IGF1R | Insulin-like growth factor 1 receptor | P08069 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 2 | 1 | 1 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Insmed | Applicant | 2005 to now |